



BlueCross BlueShield
of Alabama

Name of Blue Advantage Policy:

Bioimpedance Devices for Detection of Lymphedema

Policy #: 438

Latest Review Date: January 2022

Category: Medicine

BACKGROUND:

Blue Advantage medical policy does not conflict with Local Coverage Determinations (LCDs), Local Medical Review Policies (LMRPs) or National Coverage Determinations (NCDs) or with coverage provisions in Medicare manuals, instructions or operational policy letters. In order to be covered by Blue Advantage the service shall be reasonable and necessary under Title XVIII of the Social Security Act, Section 1862(a)(1)(A). The service is considered reasonable and necessary if it is determined that the service is:

1. *Safe and effective;*
2. *Not experimental or investigational*;*
3. *Appropriate, including duration and frequency that is considered appropriate for the service, in terms of whether it is:*
 - *Furnished in accordance with accepted standards of medical practice for the diagnosis or treatment of the patient's condition or to improve the function of a malformed body member;*
 - *Furnished in a setting appropriate to the patient's medical needs and condition;*
 - *Ordered and furnished by qualified personnel;*
 - *One that meets, but does not exceed, the patient's medical need; and*
 - *At least as beneficial as an existing and available medically appropriate alternative.*

Routine costs of qualifying clinical trial services with dates of service on or after September 19, 2000 which meet the requirements of the Clinical Trials NCD are considered reasonable and necessary by Medicare. Providers should bill **Original Medicare for covered services that are related to **clinical trials** that meet Medicare requirements (Refer to Medicare National Coverage Determinations Manual, Chapter 1, Section 310 and Medicare Claims Processing Manual Chapter 32, Sections 69.0-69.11).*

POLICY:

Effective for dates of service March 24, 2020 and after:

Blue Advantage will treat **devices using bioimpedance** (bioelectrical impedance spectroscopy) as a **non-covered benefit** and as **investigational** for use in the diagnosis, surveillance, or treatment of patients with lymphedema, including use in subclinical secondary lymphedema.

Effective for dates of service March 1, 2017 through March 23, 2020, refer to LCD L36954.

Effective for dates of service prior to March 17, 2017:

Blue Advantage will treat **devices using bioimpedance (bioelectrical impedance spectroscopy)** as a **non-covered benefit** and as **investigational** for use in the diagnosis, surveillance, or treatment of patients with lymphedema, including use in subclinical secondary lymphedema.

Blue Advantage does not approve or deny procedures, services, testing, or equipment for our members. Our decisions concern coverage only. The decision of whether or not to have a certain test, treatment or procedure is one made between the physician and his/her patient. Blue Advantage administers benefits based on the members' contract and medical policies. Physicians should always exercise their best medical judgment in providing the care they feel is most appropriate for their patients. Needed care should not be delayed or refused because of a coverage determination.

DESCRIPTION OF PROCEDURE OR SERVICE:

Secondary lymphedema may develop following treatment for breast cancer. Bioimpedance, which uses resistance to electrical current in comparing the composition of fluid compartments, could be used as a tool to diagnose lymphedema.

Lymphedema

Lymphedema is an accumulation of fluid due to disruption of lymphatic drainage. Lymphedema can be caused by congenital or inherited abnormalities in the lymphatic system (primary lymphedema) but is most often caused by acquired damage to the lymphatic system (secondary lymphedema). Breast cancer treatment is one of the most common causes of secondary lymphedema. Both the surgical removal of lymph nodes and radiotherapy are associated with development lymphedema in patients with breast cancer. In a systematic review of 72 studies (N=29,612 women), DiSipio et al (2013) reported that approximately 1 in 5 women who survive breast cancer will develop arm lymphedema. Risk factors for development of lymphedema that had a strong level of evidence were extensive surgery (i.e., axillary-lymph-node dissection, greater number of lymph nodes dissected, mastectomy) and being overweight or obese.

Diagnosis and Staging

A diagnosis of secondary lymphedema is based on history (e.g., cancer treatment, trauma) and physical examination (localized, progressive edema and asymmetric limb measurements) when other causes of edema can be excluded. Imaging, such as MRI (magnetic resonance imaging), computed tomography, ultrasound, or lymphoscintigraphy, may be used to differentiate lymphedema from others causes of edema in diagnostically challenging cases.

Table 1 lists International Society of Lymphology guidance for staging lymphedema based on "softness" or "firmness" of the limb and the changes with an elevation of the limb.

Table 1. Recommendations for Staging Lymphedema

Stage	Description
Stage 0 (subclinical)	Swelling is not evident and most patients are asymptomatic despite impaired lymphatic transport
Stage I (mild)	Accumulation of fluid that subsides (usually within 24 hours) with limb elevation; soft edema that may pit, without evidence of dermal fibrosis
Stage II (moderate)	Does not resolve with limb elevation alone; limb may no longer pit on examination
Stage III (severe)	Lymphostatic elephantiasis; pitting can be absent; skin has trophic changes

Management and Treatment

Lymphedema is treated using elevation, compression, and exercise. Conservative therapy may consist of several features depending on the severity of the lymphedema. Patients are educated on the importance of self-care including hygiene practices to prevent infection, maintaining ideal body weight through diet and exercise, and limb elevation. Compression therapy consists of repeatedly applying padding and bandages or compression garments. Manual lymphatic drainage is a light pressure massage performed by trained physical therapists or by patients designed to move fluid from obstructed areas into functioning lymph vessels and lymph nodes. Complete decongestive therapy is a multiphase treatment program involving all of the previously mentioned conservative treatment components at different intensities. Pneumatic compression pumps may also be considered as an adjunct to conservative therapy or as an alternative to self-manual lymphatic drainage in patients who have difficulty performing self-manual lymphatic drainage. In patients with more advanced lymphedema after fat deposition and tissue fibrosis has occurred, palliative surgery using reductive techniques such as liposuction may be performed.

Bioimpedance Spectroscopy

Bioimpedance spectroscopy is based on the theory that the level of opposition to the flow of electric current (impedance) through the body is inversely proportional to the volume of fluid in the tissue. In lymphedema, with the accumulation of excess interstitial fluid, tissue impedance decreases.

Bioimpedance has been proposed as a diagnostic test for this condition. In usual care, lymphedema is recognized clinically or via limb measurements. However, management via bioelectrical impedance spectroscopy has been proposed as a way to implement early treatment of subclinical lymphedema to potentially reduce its severity.

KEY POINTS:

The review has been updated regularly with MEDLINE searches, most recently through October 18, 2021.

Summary of Evidence:

For individuals who have known or suspected lymphedema who receive bioimpedance spectroscopy, the evidence includes a systematic review, one RCT, one prospective comparative observational study, and multiple uncontrolled observational studies. The relevant outcomes are test validity, symptoms, and quality of life. Diagnostic accuracy studies have found a poor correlation between bioimpedance analysis and the reference standard (volume displacement or circumferential measurement). Interim results from an ongoing RCT comparing bioimpedance with standard tape measure following treatment for breast cancer have been published. Overall, 109 of 508 (21.5%) patients received early treatment due to reaching a pre-determined threshold to trigger an intervention. A total of 12 triggering patients progressed to clinical lymphedema (2 in the bioimpedance group [4.9%] and 10 in the tape measure group [14.7%]; $P=0.130$). The RCT was limited by its open-label design and lack of reporting of important health outcomes. The single prospective comparative study found a significantly lower rate of clinical lymphedema in patients managed with bioimpedance devices but had several limitations, including nonrandomized design, lack of blinding, lack of complete data on a substantial proportion of enrolled patients, and lack of a systematic method for diagnosing lymphedema in the control group. Retrospective studies suggested that postoperative bioimpedance monitoring is feasible but provide limited information about its efficacy. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Practice Guidelines and Position Statements

National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines on Survivorship (v.3.2021), and Breast Cancer (v.1.2022), recommend education, monitoring, and referral for lymphedema management as needed. Neither guideline mentions bioimpedance.

U.S. Preventive Services Task Force Recommendations

Not applicable.

KEY WORDS:

Bioelectrical impedance testing, Bioimpedance spectroscopy, Lymphedema, bioimpedance testing, Bioimpedance analysis, BIS, Impedance plethysmography, Impedimed, LDex, Plethysmography, MoistureMeterD, SOZO

APPROVED BY GOVERNING BODIES:

Devices that have been cleared for marketing by the U.S. Food and Drug Administration through the 510(k) process to aid in the assessment of lymphedema are summarized below:

Year	Device	Manufacturer	510 (k) Number	Indication
2018	SOZO	ImpediMed (Carlsbad, CA)	K180126	For adults at risk of lymphedema. Supports the measurement of extracellular fluid volume differences between the limbs and is presented to the clinician on an L-Dex scale as an aid to their clinical assessment of lymphedema. The device is only indicated for patients who will have or who have had lymph nodes, from the axillary and/or pelvic regions, either removed, damaged or irradiated.
2015	MoistureMeterD	Delfin Technologies (Stamford, CT)	K143310	Supports local assessment of tissue water differences between affected and contralateral non-affected arm tissues to aid in forming a clinical judgment of unilateral lymphedema in women. The device is not intended to make diagnosis or predict arm lymphedema.
2007	ImpediMed L-Dex™ U400	ImpediMed, Limited	K050415	Supports the measurement of extracellular fluid

		(Carlsbad, CA)		volume differences between the arms to aid in the clinical assessment of unilateral lymphedema of the arm in women. This device is not intended to diagnose or predict lymphedema of an extremity
--	--	----------------	--	---

FDA product code: OBH

BENEFIT APPLICATION:

Coverage is subject to member’s specific benefits. Group specific policy will supersede this policy when applicable.

CURRENT CODING:

CPT Codes:

93702	Bioimpedance spectroscopy (BIS), extracellular fluid analysis for lymphedema assessment(s)
-------	--

REFERENCES:

1. Barrio AV, Eaton A, Frazier TG. A Prospective Validation Study of Bioimpedance with Volume Displacement in Early-Stage Breast Cancer Patients at Risk for Lymphedema. Ann Surg Oncol. Jun 18 2015.
2. Berlitz S, Brade J, Tuschy B, et al. Whole-body bioelectrical impedance analysis in assessing upper-limb lymphedema after breast cancer therapy. Anticancer Res. Oct 2013; 33(10):4553-4556.
3. Blaney JM, McCollum G, Lorimer J, et al. Prospective surveillance of breast cancer-related lymphedema in the first-year post-surgery: feasibility and comparison of screening measures. Support Care Cancer. Jun 2015; 23(6):1549-1559.
4. Boccardo FM, Ansaldi F, Bellini C, et al. Prospective evaluation of a prevention protocol for lymphedema following surgery for breast cancer. Lymphology 2009; 42(1):1-9.
5. Cornish BH, Chapman M, Hirst C, et al. Early diagnosis of lymphedema using multiple frequency bioimpedance. Lymphology 2001; 34(1):2-11.
6. Czerniec SA, Ward LC, Refshauge KM, et al. Assessment of breast cancer-related arm lymphedema-comparison of physical measurement methods and self-report. Cancer Invest 2010; 28(1):54-62.

7. DiSipio T, Rye S, Newman B, et al. Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis. *Lancet Oncol.* May 2013; 14(6): 500-15.
8. Dylke ES, Schembri GP, Bailey DL, et al. Diagnosis of upper limb lymphedema: development of an evidence-based approach. *Acta Oncol.* Dec 2016; 55(12):1477-1483.
9. Erdogan Iyigun Z, Selamoglu D, Alco G, et al. Bioelectrical impedance for detecting and monitoring lymphedema in patients with breast cancer. Preliminary results of the Florence Nightingale Breast Study Group. *Lymphat Res Biol.* Mar 2015; 13(1): 40-5.
10. Hayes S, Janda M, Cornish B, et al. Lymphedema secondary to breast cancer: how choice of measure influences diagnosis, prevalence, and identifiable risk factors. *Lymphology* 2008; 41(1):18-28.
11. International Society of Lymphology Executive Committee. The Diagnosis and Treatment of Peripheral Lymphedema: 2016 Consensus Document of the International Society of Lymphology. 2016; <https://journals.uair.arizona.edu/index.php/lymph/article/view/20106>. Accessed December 1, 2020.
12. Kaufman DI, Shah C, Vicini FA, et al. Utilization of bioimpedance spectroscopy in the prevention of chronic breast cancer-related lymphedema. *Breast Cancer Res Treat.* Dec 2017; 166(3): 809-815
13. Kilgore LJ, Korentager SS, Hangge AN, et al. Reducing Breast Cancer-Related Lymphedema (BCRL) Through Prospective Surveillance Monitoring Using Bioimpedance Spectroscopy (BIS) and Patient Directed Self-Interventions. *Ann Surg Oncol.* Oct 2018; 25(10): 2948-2952.
14. Koelmeyer LA, Borotkanics RJ, Alcorso J, et al. Early surveillance is associated with less incidence and severity of breast cancer-related lymphedema compared with a traditional referral model of care. *Cancer.* Mar 15 2019; 125(6): 854-862.
15. Laidley A, Anglin B. The impact of L-Dex((R)) measurements in assessing breast cancer-related lymphedema as part of routine clinical practice. *Front Oncol.* 2016; 6:192.
16. Lim SM, Han Y, Kim SI, et al. Utilization of bioelectrical impedance analysis for detection of lymphedema in breast cancer survivors: a prospective cross sectional study. *BMC Cancer.* Jul 08 2019; 19(1): 669.
17. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: Survivorship. Version 3.2021. https://www.nccn.org/professionals/physician_gls/pdf/survivorship.pdf. Accessed December 4, 2021.
- 21.
18. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: Breast Cancer. Version 1.2022. https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed December 5, 2021.
19. Oremus M, Walker K, Dayes I et al. Diagnosis and treatment of secondary lymphedema. Technology Assessment Report Project ID:LYMT0908; May 28, 2010. (Based on research conducted by the McMaster University Evidence-based Practice Center under contract to the Agency for Healthcare Research and Quality (AHRQ).) Available at: www.cmms.hhs.gov/determinationprocess/downloads/id66aTA.pdf.

20. Ridner SH, Dietrich MS, Cowher MS, et al. A Randomized Trial Evaluating Bioimpedance Spectroscopy Versus Tape Measurement for the Prevention of Lymphedema Following Treatment for Breast Cancer: Interim Analysis. *Ann Surg Oncol*. Oct 2019; 26(10): 3250-3259.
21. Shah C, Arthur DW, Wazer D, et al. The impact of early detection and intervention of breast cancer-related lymphedema: a systematic review. *Cancer Med*. Jun 2016; 5(6):1154-1162.
22. Shah C, Vicini F, Beitsch P, et al. The use of bioimpedance spectroscopy to monitor therapeutic intervention in patients treated for breast cancer related lymphedema. *Lymphology*. Dec 2013; 46(4): 184-92.
23. Smoot BJ, Wong JF, Dodd MJ. Comparison of diagnostic accuracy of clinical measures of breast cancer-related lymphedema: area under the curve. *Arch Phys Med Rehabil* 2011; 92(4):603-10.
24. Soran A, Ozmen T, McGuire KP, et al. The importance of detection of subclinical lymphedema for the prevention of breast cancer-related clinical lymphedema after axillary lymph node dissection; a prospective observational study. *Lymphat Res Biol*. Dec 2014; 12(4):289-294.
25. Stout Gergich NL, Pfalzer LA, McGarvey C, et al. Preoperative assessment enables the early diagnosis and successful treatment of lymphedema. *Cancer* 2008; 112(12):2809-19.
26. Vicini F, Shah C, Lyden M et al. Bioelectrical impedance for detecting and monitoring patients for the development of upper limb lymphedema in the clinic. *Clin Breast Cancer* 2012; 12(2): 133-7.
27. Ward LC, Dylke E, Czerniec S et al. Confirmation of the reference impedance ratios used for assessment of breast cancer-related lymphedema by bioelectrical impedance spectroscopy. *Lymphat Res Biol* 2011; 9(1):47-51.
28. Warren AG, Janz BA, Slavin SA, et al. The use of bioimpedance analysis to evaluate lymphedema. *Ann Plast Surg* 2007; 58(5):541-3.
29. Whitworth PW, Cooper A. Reducing chronic breast cancer-related lymphedema utilizing a program of prospective surveillance with bioimpedance spectroscopy. *Breast J*. Jan 2018; 24(1): 62-65.
30. Whitworth PW, Shah C, Vicini F, et al. Preventing Breast Cancer-Related Lymphedema in High-Risk Patients: The Impact of a Structured Surveillance Protocol Using Bioimpedance Spectroscopy. *Front Oncol*. 2018; 8: 197.
31. U.S. Food and Drug Administration (FDA). FDA 510(k) summary: ImpediMed IMP XCA ExtraCellular Fluid Analysis. www.accessdata.fda.gov/cdrh_docs/pdf5/K050415.pdf.
32. U.S. Food and Drug Administration (FDA). FDA 510(k) summary: ImpediMed L-Dex U400 BIS Extra Cellular Fluid Analysis. www.accessdata.fda.gov/cdrh_docs/pdf8/K080825.pdf.

POLICY HISTORY:

Adopted for Blue Advantage, July 2010

Available for comment July 23-September 6, 2010

Medical Policy Group, December 2010

Medical Policy Group, April 2011
Medical Policy Group, September 2012
Medical Policy Group, November 2012
Medical Policy Group, November 2013
Medical Policy Group, November 2014
Medical Policy Group, January 2016
Medical Policy Group, February 2017
Medical Policy Group, April 2020: Reinstated policy effective March 24, 2020.
Medical Policy Group, January 2021
Medical Policy Group, January 2022

This medical policy is not an authorization, certification, explanation of benefits, or a contract. Eligibility and benefits are determined on a case-by-case basis according to the terms of the member's plan in effect as of the date services are rendered. All medical policies are based on (i) research of current medical literature and (ii) review of common medical practices in the treatment and diagnosis of disease as of the date hereof. Physicians and other providers are solely responsible for all aspects of medical care and treatment, including the type, quality, and levels of care and treatment.

This policy is intended to be used for adjudication of claims (including pre-admission certification, pre-determinations, and pre-procedure review) in Blue Cross and Blue Shield's administration of plan contracts.